The Hidden Architecture of Chronic Illness: What Biofilms Are, Why They Matter, and How We're Learning to Dismantle Them

Scientist examining a biological sample under a microscope

Related reading on this blog: [Cistus Incanus: May Be One of Your Most Powerful Allies for Chronic Illness] | [Is Your Liver Blocking Cell Danger Response? How Phyllanthus Niruri Can Help] | [What the Research Says About Natural Antimicrobials for Lyme, Bartonella, and Babesia]

There is a conversation happening in the fringes of medicine that is slowly, steadily moving toward the center. It is not happening in mainstream clinical practice yet — not in most hospital systems, not in the typical fifteen-minute appointment, and certainly not in the guidelines that govern how the majority of physicians are trained to treat infection. But in research laboratories, in integrative clinics, in the offices of forward-thinking infectious disease specialists and holistic practitioners, a new understanding is taking shape.

It goes something like this: a significant portion of the chronic infections that are not responding to treatment may not be failing because of antibiotic resistance in the traditional sense. They may be failing because the organisms responsible for those infections have built themselves fortresses. Microscopic, organized, self-sustaining fortresses — and neither antibiotics nor the immune system were designed to breach them.

These structures are called biofilms. And if you have been living with a chronic infection that refuses to fully resolve — whether that is Lyme disease, Bartonella, a persistent urinary tract infection, recurrent sinusitis, or any number of other conditions — biofilms may be the missing piece of your story that no one has discussed with you yet.

This article is for you.

What Most People Are Never Told

When a doctor treats a bacterial infection, the working model is relatively straightforward: bacteria are free-floating, individual organisms (called planktonic cells) circulating in the body, and antibiotics are chemical agents that disrupt their cell walls, their protein synthesis, or their replication mechanisms. The bacteria die. The infection resolves.

This model is accurate — for many acute infections in otherwise healthy individuals.

But it is incomplete. It omits an entire dimension of bacterial behavior that has been known to microbiologists for decades, is now generating an enormous volume of research, and is only beginning to be factored into clinical treatment protocols. That dimension is the capacity of bacteria — and many other microorganisms — to transition from their solitary planktonic state into organized, cooperative, sessile (surface-attached) communities encased in a self-produced protective matrix.

This is a biofilm.

And the difference between treating an infection in its planktonic state versus treating one that has established a biofilm is, in some studies, the difference between a therapeutic dose and one that would need to be 500 to 1,000 times higher to achieve comparable results. That's not a small margin. That is a biological gulf.

A Brief Scientific and Historical Arc

To understand where we are, it helps to know how we got here.

Bacteria living in organized surface communities were first observed in 1683 by Dutch microscopist Antonie van Leeuwenhoek, who scraped material from his own teeth and placed it under a primitive lens. He described the organisms he saw with wonder. He had no framework to understand what he was looking at, but in that moment, he became the first human being to witness dental plaque — which is, as we now understand, one of the most complex and clinically relevant biofilms in existence.

Nearly three centuries passed before the concept of biofilm began to gain scientific traction. In the early 1970s, Danish microbiologist Nils Høiby made a critical observation: patients with cystic fibrosis suffered from persistent, severe lung infections caused by Pseudomonas aeruginosa that stubbornly resisted every antibiotic treatment available. When he examined lung tissue, he found the bacteria were not free-floating — they were organized into protective aggregates. This was one of the first documented clinical recognitions of biofilm as a driver of treatment-resistant human disease.

The modern biofilm era was formally inaugurated in 1999 when J. W. Costerton, P. S. Stewart, and E. P. Greenberg published a landmark paper in the journal Science titled "Bacterial Biofilms: A Common Cause of Persistent Infections." This was not fringe literature. Science is one of the most prestigious peer-reviewed publications in the world. In that paper, the authors articulated what many researchers had been observing: that biofilm formation and its inherent resistance to antimicrobial agents were at the foundation of many chronic and persistent bacterial infections, and that biofilm communities behaved with a degree of structural differentiation and cooperative community behavior that had never been fully appreciated.

That paper has now been cited thousands of times. And yet, two and a half decades later, biofilm is still not part of the standard clinical conversation about why some infections persist.

What a Biofilm Actually Is

If you want to understand biofilm at a gut level, picture this.

A group of bacteria attach to a surface — which in the human body might be joint tissue, a heart valve, the lining of a sinus cavity, a section of intestinal wall, nerve tissue, or any number of other structures. Once attached, they begin communicating through a sophisticated chemical signaling network called quorum sensing. They are taking stock of their numbers and their environment, essentially deciding: is there enough of us here to build?

When the threshold is reached, they begin secreting a complex matrix of extracellular polymeric substances — a gel-like architecture composed of polysaccharides, proteins, lipids, and extracellular DNA. This matrix is not passive scaffolding. It is an active, responsive protective structure that does several things simultaneously:

• It physically blocks the penetration of antibiotics into the colony's interior

• It creates local microenvironments with altered pH and oxygen levels that render many antibiotics chemically inactive

• It provides a refuge for dormant, low-metabolism persister cells that standard antibiotics are unable to kill even under ideal conditions

• It shields the bacteria from immune surveillance — white blood cells cannot effectively engulf organisms embedded in biofilm matrix the way they can free-floating bacteria

• It allows the colony to horizontally transfer genetic information, including antibiotic resistance genes, between organisms

Inside the biofilm, the bacteria are operating as a multicellular organism. They are not the isolated, individual cells that antibiotic pharmacology was designed to target. They are a collective — with division of labor, protective architecture, and survival strategies that evolved over hundreds of millions of years.

A 2024 review published in the International Journal of Molecular Sciences noted that the resistance of microbial cells within biofilms to the host immune system, antibiotics, and other antimicrobial agents can increase by hundreds of times compared to their free-floating counterparts. Not percent. Times.

Biofilm Is Everywhere — Not Just in Lyme Disease

Here is where I want to pause and make sure the scope of this problem is fully apparent. Biofilm is not a Lyme disease issue. It is not even primarily an infectious disease issue in the narrow sense. Biofilm is a fundamental biological phenomenon that is now being identified as a contributing factor in a remarkable range of chronic human conditions.

A 2024 review estimated that biofilm is implicated in more than 80% of persistent infectious diseases. Let that sit for a moment.

In the oral cavity, dental plaque — the substance your dentist mechanically scrapes from your teeth — is a classic biofilm community. The acid-producing bacteria within dental plaque, principally Streptococcus mutans, demineralize tooth enamel through a process that is entirely biofilm-mediated. Research has also connected periodontal (gum) disease — itself a biofilm-driven chronic infection — to a growing number of systemic conditions, including cardiovascular disease, diabetes, rheumatoid arthritis, osteoporosis, pulmonary disorders, and Alzheimer's disease. The American Dental Association has reported connections between oral health and systemic disease numbering in the hundreds. The mouth is not separate from the body. Its biofilm is not separate from your chronic illness.

In the urinary tract, the notorious recurrence pattern of UTIs in many patients — particularly women who complete a full course of antibiotics only to find themselves symptomatic again within weeks — is increasingly understood as a biofilm phenomenon. Uropathogenic E. coli establish intracellular biofilm-like reservoirs within bladder epithelial cells that antibiotics penetrate poorly, allowing the infection to re-seed itself from within.

In chronic sinusitis, biofilm on the sinus mucosa has been identified in studies of patients who fail to respond to repeated antibiotic courses, and is now understood to be a primary reason for treatment failure in this remarkably common condition.

In the cardiovascular system, infective endocarditis — infection of the heart valves — is a biofilm disease. So are many catheter-associated bloodstream infections, one of the most dangerous and costly nosocomial (hospital-acquired) infection categories.

In the joints, biofilm formation on prosthetic implants is a leading cause of implant failure and deep surgical site infection — a problem that costs billions of dollars in additional medical procedures annually and causes immeasurable patient suffering.

In cystic fibrosis, where Dr. Høiby first recognized the problem, persistent Pseudomonas aeruginosa lung infection drives catastrophic respiratory decline in patients — and the infection persists precisely because the organism builds biofilms in the airway that no antibiotic concentration clinically achievable can fully eradicate.

And in Lyme disease and tick-borne co-infections — the terrain most familiar to those of us navigating this path — biofilm has emerged as one of the most compelling and clinically significant pieces of the treatment-resistance puzzle.

Borrelia and Biofilm: The Evidence

The recognition that Borrelia burgdorferi is capable of forming biofilm has not been fast or uncontested. It has been built, brick by careful brick, through laboratory research, animal studies, and — most compellingly — through human autopsy evidence.

The initial characterization of Borrelia biofilm formation in vitro was published in 2012, establishing for the first time with substantial evidence that the organism can transition into biofilm-like structures exhibiting the hallmarks of true biofilm: structural rearrangement, protective matrix secretion, and the development of a highly resistant bacterial population at the core.

The most sobering evidence came from a post-mortem case study published in 2019. Researchers analyzed autopsy tissue from a 53-year-old woman who had been culture-confirmed as Lyme disease positive and had received extensive antibiotic treatment over 16 years — yet never recovered. When her tissues were examined with advanced imaging and molecular techniques following her death, Borrelia burgdorferi was found in the brain, heart, kidney, and liver. Critically, the bacterial aggregates identified in her tissues contained alginate on their surfaces — a well-established biological marker of true biofilm — suggesting the organisms had been sheltering in biofilm communities throughout her illness, where no antibiotic reached them effectively, for over a decade and a half.

Research published in Discovery Medicine in 2019 added further clinical dimension to this: Borrelia biofilm microcolonies not only resisted current Lyme antibiotics — including doxycycline and even intravenous ceftriaxone — but caused more severe disease in mouse models than either the spirochetal or persister cell forms of the organism. The biofilm form was the most pathogenic and the most treatment-resistant of all three morphological variants.

This is the intersection of persistent illness, biofilm biology, and failed conventional treatment that practitioners like Dr. Richard Horowitz have been working within for years — and from which a new generation of treatment strategies is emerging.

Dr. Richard Horowitz and the Dapsone Story: Thinking Outside the Antibiotic Box

Dr. Richard Horowitz is a board-certified internist based in Hyde Park, New York, with over 41 years of clinical experience treating tick-borne illness and more than 13,000 patients with chronic Lyme and associated conditions in his practice. He is also the author of the New York Times bestseller Why Can't I Get Better? and recently published a tenth peer-reviewed study on what has become his signature treatment approach: dapsone combination therapy.

Dapsone is a synthetic antimicrobial that was developed in the 1940s and has been used clinically for decades to treat infections with a familiar characteristic: they are persistent, difficult to eradicate, and poorly responsive to standard antibiotic protocols. Leprosy, caused by Mycobacterium leprae, and the treatment-resistant forms of tuberculosis are the most well-known examples. What these conditions share with chronic Lyme disease — and what appears to be the mechanism linking dapsone's effectiveness across all of them — is the presence of persister forms of the organism and, in the case of Borrelia, active biofilm.

Dapsone's mechanism in this context is not simply antibacterial in the conventional sense. It acts as what researchers call a "persister drug" — an agent capable of targeting the dormant, low-metabolism bacterial cells that standard antibiotics cannot. It also has meaningful anti-inflammatory properties, anti-malarial activity relevant to Babesia co-infection, and strong penetration of the central nervous system — a critical feature given the neurological burden many chronic Lyme patients carry.

In Horowitz's groundbreaking 2020 in vivo clinical study, an eight-week course of dapsone combined with doxycycline and rifampin produced symptom improvement in 98% of patients with chronic Lyme disease and post-treatment Lyme disease syndrome. A follow-up double-dose protocol showed that approximately 50% of patients who completed the full course experienced sustained symptom remission lasting six months or longer without further antimicrobial treatment. He has now published ten peer-reviewed studies involving more than 365 patients, with cognitive improvement as the most consistently documented outcome.

Most recently — and this stops me in my tracks every time I share it — Horowitz published the first documented case of Alzheimer's disease biomarker reversal in a chronic Lyme patient treated with dapsone combination therapy. Using newly validated blood biomarkers for phosphorylated tau and amyloid beta ratios — the same markers being tracked in Alzheimer's research — treatment of the underlying Borrelia biofilm resulted in normalization of these markers. This is not a claim that Lyme causes all Alzheimer's. But it is a profound signal that the persistent, biofilm-harbored spirochetal infection has broader neurological consequences than have been appreciated, and that addressing it may have neurological benefits extending beyond what was previously imagined.

The story of dapsone in Lyme disease is a story about recognizing that the same principle Horowitz applied to leprosy and tuberculosis a century ago — that persistent, hard-to-treat infections sometimes require agents specifically capable of reaching dormant and protected bacterial populations — applies with equal force to Borrelia in its biofilm form.

Disulfiram: When an Alcoholism Drug Becomes the Best Biofilm Fighter in the Room

The story of disulfiram in Lyme disease begins with a library screening project. Dr. Jayakumar Rajadas, director of Stanford University's BioADD lab, was on a mission: to identify FDA-approved compounds that could kill the persister and biofilm forms of Borrelia burgdorferi that conventional antibiotics consistently failed to reach. His team systematically screened 4,366 FDA-approved drugs for activity against the organism.

The top candidate was not a new antibiotic. It was not a novel pharmaceutical. It was tetraethylthiuram disulfide — better known as disulfiram, or Antabuse — a drug approved for helping people maintain sobriety from alcohol by causing intensely unpleasant reactions to its consumption. It has been on the market since 1951.

Why does disulfiram work against Borrelia persister and biofilm forms? The mechanisms are still being studied, but several factors appear relevant. Disulfiram and its metabolites disrupt copper-mediated biochemical pathways that Borrelia depends on for survival; they also damage bacterial cell membranes and interfere with key enzyme systems. Unlike many antibiotics, disulfiram achieves excellent tissue penetration and crosses the blood-brain barrier readily — bringing its antimicrobial activity directly into the immunologically privileged compartments where Borrelia most effectively hides.

In animal studies, disulfiram completely eliminated Borrelia burgdorferi from cardiac and urinary bladder tissue by day 28 post-infection. A human retrospective study of 71 patients found that 92.5% endorsed net benefit. In a clinical trial protocol, disulfiram demonstrated activity against both the actively replicating spirochetal form and the quiescent persister forms that standard antibiotics leave intact.

For those on my blog who have been following my article on disulfiram's role in Lyme treatment, this is the biological foundation for why a drug designed for addiction medicine is now being used off-label by some of the most sophisticated Lyme-literate clinicians in the country. Biofilm is the reason. Persister cells are the reason. The conventional antibiotic framework, applied to a biofilm-forming organism, was never going to be sufficient for a meaningful subset of patients.

The Controversy — And Why It Matters That We Name It

I said at the outset that this remains a controversial area, and I want to honor that honestly.

The mainstream infectious disease consensus — represented by organizations like the IDSA — does not currently recognize biofilm as an established driver of chronic Lyme disease in human patients. The debate about whether "chronic Lyme disease" as a persistent infection is real at all has been contentious for decades, and the biofilm literature is caught up in that broader disagreement.

Here is what is not controversial: Borrelia forms biofilm in vitro. That is reproducibly demonstrated. What remains debated is the degree to which that in vitro phenomenon translates into clinically significant biofilm colonization in human tissue, and whether targeting biofilm-specific mechanisms leads to better patient outcomes in well-designed controlled trials.

What is also not controversial: biofilms are now implicated in the majority of chronic human infections broadly — dental plaque, implant infections, chronic sinusitis, endocarditis, cystic fibrosis lung disease, recurrent UTI. The biology is not in dispute in those contexts. What is still being established is the specific degree of biofilm contribution in tick-borne illness and whether the treatment approaches being explored in clinical practice can be validated in controlled trials.

The autopsy evidence — Borrelia biofilm with the alginate marker, found in multiple major organs of a patient treated with antibiotics for 16 years — is difficult to argue with. It does not tell us how often this occurs or in what proportion of patients. But it confirms the capacity is real, the persistence is real, and the treatment resistance associated with biofilm is real.

This is an area of active, evolving science. The honest position is: the evidence is compelling and growing, the clinical experience of thoughtful practitioners is pointing in a consistent direction, and we are not yet at the place where definitive randomized controlled trial data settles every question. That is not a reason to wait. It is a reason to stay informed.

Natural Biofilm Disruptors: What the Research Supports

This is where the focus of my work, and the focus of several recent articles on this blog, becomes directly relevant. Because while the pharmaceutical approaches to biofilm — dapsone, disulfiram, daptomycin — are genuine and meaningful tools, there is a growing body of research on natural botanical and nutraceutical agents with biofilm-disrupting properties. And several of them are already woven into the protocols I use and write about.

A foundational strategic principle before we get into specifics: disrupting a biofilm is not the same as killing bacteria. These are two sequential tasks. Biofilm disruptors break down the protective matrix and expose the organisms within. Antimicrobial agents — whether pharmaceutical or botanical — then kill those newly exposed organisms. The most effective approach uses both, in that order, and ideally agents that have both properties themselves or strong synergistic partners that cover both.

Cistus incanus (Pink Rock Rose)

I have written a dedicated article on Cistus incanus for this blog, and for good reason — it is one of the botanicals with the most compelling profile for tick-borne illness and biofilm-related disease. Here I want to place it in the specific context of biofilm disruption.

Cistus incanus is extraordinarily rich in polyphenols — including ellagitannins, catechins, flavonoids, and gallic acid derivatives. These compounds are understood to interfere with biofilm formation and stability through a specific mechanism: they disrupt the surface protein adhesion that bacteria rely on to establish and maintain biofilm architecture. By targeting these adhesion proteins, Cistus polyphenols can both prevent new biofilm formation and destabilize existing structures.

Research has demonstrated that Cistus incanus essential oil and extract have inhibitory effects against actively growing Borrelia burgdorferi — and, importantly, the inhibitory compound that demonstrates the strongest anti-Borrelia activity is carvacrol, the same active constituent found in oregano. In the context of biofilm specifically, the polyphenol-dense composition of Cistus is thought to act at the matrix level, making the structural integrity of established biofilms more fragile and thereby increasing bacterial exposure to both immune surveillance and antimicrobial agents.

For those of us dealing with chronic tick-borne illness, Cistus incanus stands as a botanically grounded, historically documented, and research-supported ally in what I think of as the "open the fortress" phase of treatment — the phase that must happen before the killing agents have their best opportunity.

Phyllanthus niruri (Chanca Piedra / Stone Breaker)

If you've read my article on Phyllanthus niruri and Cell Danger Response, you already know how meaningful this herb is within my framework. In that piece I focused primarily on its liver-protective and CDR-resolving properties. Here I want to highlight its emerging role in the biofilm conversation.

Research published in 2023 in the Journal of King Saud University: Science demonstrated that silver nanoparticles synthesized from Phyllanthus niruri leaf extract significantly inhibited biofilm formation by a range of clinically significant bacteria — including Pseudomonas aeruginosa, Bacillus cereus, E. coli, and Staphylococcus aureus. The nanoparticle preparation also showed activity against drug-resistant strains including MRSA, vancomycin-resistant enterococci, and carbapenem-resistant Enterobacterales.

Separate research has demonstrated Phyllanthus niruri's antibacterial efficacy against cariogenic (cavity-causing) bacteria associated with the oral dental biofilm — a meaningful connection given how deeply oral biofilm health reflects systemic biofilm burden.

Phyllanthus niruri's biofilm-relevant properties are thought to connect to its rich phytochemical profile, including phyllanthin, hypophyllanthin, geraniin, and a broad array of tannins and polyphenols that disrupt bacterial membrane integrity, interfere with quorum sensing (the chemical communication system bacteria use to coordinate biofilm formation), and reduce the structural cohesion of established biofilm matrices.

The deeper picture of this herb continues to emerge. Its nickname "Stone Breaker" — historically referencing kidney stone dissolution — may, in a broader metaphorical and possibly literal sense, speak to a generalized capacity to dismantle mineralized or structured biological structures. The biofilm research is in its earlier stages for Phyllanthus specifically, but its multi-mechanism antimicrobial activity and supportive liver effects make it a meaningful part of a comprehensive protocol.

N-Acetylcysteine (NAC)

N-acetylcysteine is one of the most well-researched biofilm-disrupting compounds in the literature, and its mechanism is both specific and elegant. Biofilm matrices contain significant quantities of extracellular DNA and sulfur-bond-dependent structural proteins.

NAC, as a thiol-containing compound, cleaves disulfide bonds within the matrix — essentially chemically cutting the structural connections that hold the biofilm architecture together. This mucolytic (matrix-dissolving) action physically degrades the biofilm and increases its permeability.

Multiple studies have demonstrated NAC's biofilm-disrupting activity against a range of organisms including Pseudomonas aeruginosa, Staphylococcus aureus, E. coli, and others. A 2023 study published in the Journal of Microbiology and Biotechnology evaluated a blend of enzymes and botanical extracts — including NAC alongside antimicrobial cranberry, berberine, rosemary, and peppermint extracts — against established Borrelia burgdorferi biofilm. The combination produced significant disruption of Borrelia biofilm mass and metabolic activity, with reductions in structural integrity across the tested strains.

NAC is safe, widely available, and carries additional benefits relevant to chronic illness — it is a precursor to glutathione, the body's master antioxidant, which is typically depleted in those with persistent infectious burden and heavy toxic load.

For practical application: NAC and other biofilm-disrupting agents are most effective when taken on an empty stomach, typically 20-30 minutes before antimicrobial agents. This timing allows the disruptors to weaken the matrix before the killing agents arrive — sequencing that mirrors military strategy more than it resembles how we typically think about taking supplements.

Proteolytic Enzymes: Serrapeptase and Nattokinase

The biofilm matrix is constructed in part from proteins — fibrin, structural amyloids, and other protein scaffolding that provides rigidity and cohesion to the community. Proteolytic (protein-digesting) enzymes offer a targeted approach to dismantling this architecture.

Serrapeptase is a serine protease originally derived from a beneficial organism found in silkworms. In laboratory studies on Staphylococcus aureus biofilm, serrapeptase demonstrated the ability to degrade the amyloid proteins used to build and stabilize biofilm structures in a dose-dependent manner. It appears to act at the early stages of biofilm formation and also on established matrices.

Nattokinase, derived from fermented soybeans (natto), shares a protein-dissolving mechanism with serrapeptase while also supporting circulation and helping dissolve fibrin — a protein often found incorporated into biofilm matrices in vascularized tissue. In combination, these enzymes can address multiple protein components of the matrix simultaneously.

Both are used clinically as biofilm-disrupting agents and are generally well-tolerated when taken on an empty stomach. Those on pharmaceutical blood thinners should work with their physician before using either, as both enzymes have fibrinolytic activity.

EDTA (Ethylenediaminetetraacetic Acid)

Metal ions — particularly calcium, magnesium, iron, and zinc — serve as structural cross-linkers within biofilm matrices, providing much of the mechanical stability that makes them resistant to disruption. EDTA is a chelating agent that binds these metal ions with high affinity, effectively pulling the structural scaffolding out from under the biofilm. Without its mineral cross-links, the matrix loses cohesion and becomes far more permeable to both immune cells and antimicrobial compounds.

EDTA has been used in biofilm disruption protocols for medical device infections and is increasingly recognized as a meaningful adjunct in clinical infection management. At high intravenous doses, EDTA requires medical supervision because it affects systemic mineral balance. In lower-dose oral or topical preparations used in supplement protocols, it is generally well-tolerated, though practitioner guidance is still appropriate.

Baicalein (Scutellaria baicalensis) + Monolaurin

I covered both of these in detail in my companion article on natural antimicrobials, and they deserve specific mention here in the biofilm context because their documented biofilm-disrupting activity is among the most research-supported in the natural medicine landscape.

Baicalein — the active flavonoid from Chinese skullcap — demonstrated activity against all three morphological forms of Borrelia burgdorferi, including its biofilm form. When combined with luteolin, the pairing eliminated approximately 90% of active and persistent Borrelia and eradicated 50% of mature Borrelia biofilm — a level of biofilm disruption that is genuinely extraordinary and exceeds many pharmaceutical compounds tested against the same target.

Monolaurin — a fatty acid derivative most naturally abundant in coconut oil — demonstrated significant efficacy against Borrelia burgdorferi and Borrelia garinii biofilm forms specifically when tested alongside baicalein. This is notable because many agents that perform well against planktonic (free-floating) forms of Borrelia show minimal impact against the biofilm form. Monolaurin and baicalein together appear to be among the strongest documented natural combinations against established Borrelia biofilm.

Oregano (Carvacrol), Garlic (Allicin), Clove (Eugenol), and Cinnamon (Cinnamaldehyde)

These four essential oil-derived antimicrobials, covered at length in my antimicrobials article, carry documented activity not only against the planktonic and persister forms of Borrelia but also against biofilm microcolonies specifically.

Carvacrol (oregano's primary active component, shared with Cistus incanus and thyme) has demonstrated biofilm-disrupting activity against Borrelia. Allicin (garlic) ranked among the top performers against Borrelia stationary phase cultures — the precursor state to mature biofilm. Clove, cinnamon, and oregano were three of the top five oils tested against Borrelia persister cells, with clove, oregano, and cinnamon achieving complete eradication with no regrowth in subcultures — a result that pharmaceutical anti-persister drugs like daptomycin did not achieve in the same testing conditions.

For those incorporating essential oil preparations into their protocols, emulsified forms designed for internal therapeutic use are critical — these are vastly different in bioavailability and gastrointestinal tolerability from standard cooking-grade products.

Berberine (Berberis vulgaris and related plants)

Berberine carries a dual mechanism highly relevant to biofilm: it disrupts quorum sensing — the bacterial communication system that coordinates biofilm formation — and has direct bactericidal activity against organisms within established biofilms. Research has confirmed its anti-biofilm activity against multiple organisms, including those relevant to dental biofilm, recurrent UTI, and tick-borne illness.

Berberine's mechanism of interfering with quorum sensing is particularly interesting because quorum sensing is what allows individual bacteria to coordinate the transition from free-floating planktonic behavior to collective biofilm formation. Agents that interrupt this signaling can theoretically prevent new biofilm development while also destabilizing existing communities. Berberine is one of the most studied natural quorum-sensing inhibitors available.

Stevia (Whole Leaf — Specific Preparations Only)

This is an unusual entry and one worth being precise about. Specific whole-leaf stevia preparations — not the commercial sweetener — have demonstrated efficacy against the biofilm form of Borrelia burgdorferi in laboratory research. Studies found that stevia leaf was also shown, in combination with three different antibiotics, to significantly reduce Borrelia biofilm in vitro.

The critical caveat, as emphasized in the research, is that preparation specificity matters enormously. Not all stevia products produced these results. The commercial stevia sweetener has not been shown to have these properties. This is a place where product quality and form are everything.

Iodine (as Kelp)

Kelp-derived iodine appeared as a component in the combination Borrelia biofilm study discussed in my antimicrobials article — the six-agent combination (baicalein, luteolin, rosmarinic acid, monolaurin, cis-2-decenoic acid, and iodine from kelp) that reduced spirochete burden in animal tissues by approximately 75% over four weeks and produced measurable normalization of inflammatory cytokines. Iodine's contribution to the combination is thought to relate to its broad-spectrum antimicrobial activity and potentially its role in destabilizing the biofilm matrix, though more specific research on Borrelia biofilm and iodine specifically is warranted.

The Herxheimer Response: When Disruption Feels Like Getting Worse

Anyone who has worked with biofilm-disrupting protocols in the context of chronic infection will tell you about this, and it deserves an honest discussion.

When biofilm is disrupted, the organisms sheltering within it are suddenly exposed — and can die in significant numbers in a relatively short period. The immune system, which had limited visibility into the protected colony, now encounters a wave of microbial antigens and cellular debris. The result is a systemic inflammatory response — colloquially known as a Herxheimer reaction, or "herx" — that can produce temporary worsening of symptoms: fatigue, flu-like aching, brain fog, night sweats, increased pain, and mood changes.

This reaction is not a sign that the protocol is harming you. It is typically a sign that it is working. However, it must be respected and managed carefully. Opening biofilm too rapidly in someone whose detoxification pathways are already overwhelmed — whose liver is under stress, whose lymphatic drainage is sluggish, whose gut is compromised — can produce reactions that are genuinely difficult to manage.

This is one of the central reasons why the sequencing and phasing of biofilm protocols matters as much as the specific agents used. It is also why, in my own practice and personal experience, I give so much attention to detoxification capacity and drainage before aggressively targeting biofilm. You have to open the drainage pathways before you pull the walls down.

This is where CellCore Biosciences protocols align beautifully with the biofilm biology. The systematic approach — drainage, detoxification, then targeted antimicrobial and anti-biofilm work — is not arbitrary. It reflects a genuine understanding of what happens physiologically when biofilm colonies are disrupted and the organisms within them are released into circulation.

Quorum Sensing: The Bacterial Internet

One final concept worth introducing because it opens an additional strategic window in treatment: quorum sensing.

Bacteria do not form biofilms spontaneously or individually. They form them through collective decision-making. Before the first bacteria in a colony transition to biofilm mode, they assess their local population density by releasing and detecting chemical signal molecules called autoinducers. When the concentration of autoinducers in the environment reaches a threshold, the bacteria "know" they have sufficient numbers to build — and the genetic programs for biofilm formation switch on.

Disrupting this chemical communication is called quorum quenching, and it represents a fundamentally different strategy than either killing bacteria directly or dismantling established biofilm. By interfering with the signaling system before the decision to build biofilm is made, quorum quenching agents can theoretically prevent biofilm formation from occurring in the first place.

Several natural compounds have demonstrated quorum-sensing inhibitory activity — including berberine, resveratrol (Japanese knotweed), garlic-derived compounds, certain polyphenols in Cistus incanus, and various flavonoids. The research in this area is still maturing, particularly with respect to tick-borne illness specifically, but it offers another angle for those building comprehensive anti-biofilm protocols.

Where This Leaves Us

The recognition of biofilm as a major driver of chronic, treatment-resistant infection is not a fringe idea waiting for legitimacy. It is an established biological reality in multiple clinical contexts, supported by decades of increasingly sophisticated research, that is now being actively applied — with meaningful clinical results — in the context of tick-borne illness.

What remains evolving is the specific evidence base for Borrelia biofilm in human tissue, the optimal treatment protocols for disrupting it, and the degree to which natural biofilm-disrupting agents alone versus in combination with pharmaceutical approaches can achieve durable clinical improvement in the most complex cases.

What is not evolving — because the trajectory is clear — is the direction of this science. Biofilm research is one of the fastest-growing areas in all of microbiology and infectious disease medicine. The tools we have now — from dapsone combination therapy and disulfiram to Cistus incanus, Phyllanthus niruri, baicalein, monolaurin, NAC, and proteolytic enzymes — represent the current leading edge of a therapeutic conversation that will only deepen.

For those of you reading this who have done everything right and still don't feel well — who have completed antibiotics, changed your diet, reduced your stress, and still wake up every morning carrying a body that doesn't work the way it should — I want you to know: the biology does not say you are imagining it. The biology says the organisms causing your illness may have built structures specifically designed to hide from every tool your doctors have tried.

That is not a counsel of despair. It is an invitation to go deeper — to understand the full architecture of what you are dealing with, so that every therapeutic choice you make is aimed at the actual target.

Biofilm is the target that has been hiding in plain sight. And the science is finally catching up with what it demands of us.

This article is for educational purposes and does not constitute medical advice. Please work with a qualified practitioner familiar with tick-borne illness and biofilm-related conditions before beginning or modifying any treatment protocol.

Key references consulted for this article include: Costerton, Stewart & Greenberg (1999), Science; Sapi et al. (2012), University of New Haven Lyme Disease Research Group; Middelveen et al. (2019), Antibiotics (MDPI); Feng et al. (2019), Discovery Medicine; Horowitz et al. (2020–2026), multiple publications; Pothineni et al. (2016), Stanford BioADD; Rajadas et al. (2016), Stanford; Hu (2024), IJMS; Mendhe et al. (2023), Cureus; Kumar et al. (2023), JKSU-Science.

Ann-Marie Gunn holds a Masters of Science degree in Holistic Nutrition and is CellCore Biosciences Practitioner. After contracting Lyme disease and eight co-infections, she brings both professional expertise and personal experience to supporting clients through complex tick-borne illness recovery.